Traws Pharma Inc Total Liabilities
Traws Pharma Inc total liabilities. Based on the latest financial reports, Traws Pharma Inc (TRAW) has total liabilities worth $9.78 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check asset resilience ratio of Traws Pharma Inc to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Traws Pharma Inc (2011–2025)
Total liabilities of Traws Pharma Inc from 2011 to 2025. This chart illustrates how Traws Pharma Inc's total liabilities have evolved over time, based on quarterly financial data.
Traws Pharma Inc Competitors by Total Liabilities
The table below lists competitors of Traws Pharma Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
STREAMPLAY STUDIO LTD.
F:GIX0
|
Germany | €1.45 Million |
|
Bindi Metals Ltd
AU:BIM
|
Australia | AU$138.04K |
|
ARK Resources Bhd
KLSE:7007
|
Malaysia | RM41.45 Million |
|
Ignite Ltd
AU:IGN
|
Australia | AU$4.89 Million |
|
Strategem Capital Corp
V:SGE
|
Canada | CA$54.00K |
|
CARLSON INV. ZY 13
F:2HB
|
Germany | €1.12 Million |
|
UNITH LTD.
F:CM30
|
Germany | €1.61 Million |
|
Carmell Therapeutics Corporation
NASDAQ:CTCX
|
USA | $7.14 Million |
Liability Composition Analysis (2011–2025)
This chart breaks down Traws Pharma Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see TRAW asset base.
Liquidity & Leverage Metrics
Traws Pharma Inc Total Liabilities Ratios Explained
Traws Pharma Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.93 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 5.78 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.85 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Traws Pharma Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Traws Pharma Inc (2011–2025)
The table below shows the annual total liabilities of Traws Pharma Inc from 2011 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $11.25 Million | -80.13% |
| 2024-12-31 | $56.59 Million | +371.17% |
| 2023-12-31 | $12.01 Million | +8.57% |
| 2022-12-31 | $11.06 Million | +18.22% |
| 2021-12-31 | $9.36 Million | -32.24% |
| 2020-12-31 | $13.81 Million | +14.14% |
| 2019-12-31 | $12.10 Million | -3.48% |
| 2018-12-31 | $12.54 Million | -20.86% |
| 2017-12-31 | $15.84 Million | -12.52% |
| 2016-12-31 | $18.11 Million | +43.64% |
| 2015-12-31 | $12.61 Million | -46.85% |
| 2014-12-31 | $23.71 Million | -2.22% |
| 2013-12-31 | $24.25 Million | -89.98% |
| 2012-12-31 | $242.16 Million | +69.48% |
| 2011-12-31 | $142.88 Million | -- |
About Traws Pharma Inc
Traws Pharma, Inc., a clinical-stage biopharmaceutical company, develops small synthetic molecules for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID-19 that are designed to address treatment resistance, such as TRX01 (Ratutrelvir), an inhibitor in development for the treatment of COVID-19; and Tivoxavir marboxil, an endonu… Read more